Mammoth Biosciences Presents AACC 2021 Disruptive Technology Award Finalist CRISPR-Based Detection Platform

By LabMedica International staff writers
Posted on 29 Sep 2021

Illustration

Mammoth Biosciences (San Francisco, CA, USA) presented its revolutionary CRISPR-based detection platform that is enabling limitless testing possibilities and was also one of the AACC 2021 Disruptive Technology award finalists.

Mammoth has catalyzed a new approach to molecular diagnostics, called DETECTR. Based on CRISPR, this programmable platform acts as a search engine for biology and is capable of finding and identifying any nucleic acid sequence in the genome. Using proprietary technology licensed exclusively from the University of California, Berkeley and developed internally, Mammoth is working on multiple form factors and test targets from infectious diseases to cancer. For example, DETECTR was configured in less than two weeks to detect SARS-CoV-2, demonstrating the platform’s ability to be quickly tailored to identify any DNA or RNA target. The resulting product, DETECTR BOOST, is a reagent kit that when combined with standard laboratory automation provides labs with unparalleled high throughput molecular testing.

Mammoth was also one of the AACC 2021 Disruptive Technology award finalists. AACC's Disruptive Technology Award Competition recognizes innovative testing and disruptive technology solutions that improve patient care through diagnostic performance or access to high quality testing. It provides an opportunity for early to mid-stage start-ups in the medical device, diagnostic, or digital health/health IT spaces to showcase their technology and present to a large audience and a panel of judges.

Related Links:
Mammoth Biosciences

Visit expo >

Platinum Member

Automated Coagulation Analyzer

Hemolumi H6

Gold Member

Aspiration System

VACUSAFE

Automatic CLIA Analyzer

Shine i6000

HPV Test

Allplex HPV28 Detection

Latest AACC 2021 News

Channels

Clinical Chemistry

view channel

Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Image: Lead author Professor Chamindie Punyadeera. (Image Credit: Griffith University)

Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules

Lung nodules are frequently detected during imaging, but distinguishing malignant from benign findings can require invasive procedures. Some patients undergo biopsies, bronchoscopy, or surgery before learning... Read more

Blood Biomarker Patterns Could Support Monitoring of Anti-Amyloid Treatment

Patients with early-stage Alzheimer’s disease may receive anti-amyloid therapy to clear amyloid protein deposits from the brain. These treatments can slow disease progression, but they do not cure the... Read more

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Molecular Diagnostics

view channel

Hematology

view channel

New Donor Genetic Marker May Help Predict Stem Cell Transplant Success

Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more

Image Credit: American Society of Hematology

Updated Ferritin Thresholds Improve Detection of Iron Deficiency

Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read more

New Automated Hemostasis Systems Become Available Across US Laboratories

Hemostasis testing supports critical decisions in surgery, anticoagulation management, and the evaluation of bleeding and thrombotic disorders, but laboratories continue to face rising volumes and complex... Read more

Image: Acute myeloid leukemia is an aggressive blood cancer in which relapse remains a major challenge, making MRD detection critical for risk assessment and treatment planning (Image Credit: Shutterstock)

Variation in AML Residual Disease Testing Prompts Push for Standardization

Acute myeloid leukemia (AML) is an aggressive blood cancer in which relapse after therapy remains a persistent challenge, making measurable residual disease (MRD) detection central to risk assessment and... Read more

Immunology

view channel

Blood Test Differentiates Bacterial and Viral Infections in Febrile Infants

Fever in infants younger than 3 months is treated as a medical emergency because infections can become life-threatening while the immune system is still developing. Emergency department teams must quickly... Read more

New Autoantibody Test Targets Pre-Symptomatic Type 1 Diabetes Screening

Type 1 diabetes is often first recognized only after substantial beta-cell destruction, sometimes presenting as diabetic ketoacidosis. Population-scale screening could identify children at elevated risk... Read more

Image: The testing approach is designed for people with HIV whose viral load rises while taking dolutegravir, aiming to limit the accumulation and spread of drug resistance in resource-limited settings. (Image Credit: Shutterstock)

HIV Monitoring Strategy Uses Drug Levels to Guide Resistance Testing

HIV viral load can rise during antiretroviral therapy for reasons that do not necessarily indicate drug resistance. Clinicians must distinguish between treatment nonadherence and resistance before deciding... Read more

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel

$Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)$

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Pathology

view channel

Image: longer and is more labor-intensive. The approach images fresh, unprocessed tissue in under a minute, avoiding the slower, labor-intensive staining required in conventional pathology (Image Credit: Adobe Stock)

New AI Model Maps Where Glioblastoma Could Return After Surgery

Glioblastoma is the most common malignant brain tumor in adults and the most lethal, with median survival of about 17 months after diagnosis. Even after surgeons remove all visible tumor and patients receive... Read more

Multimodal AI Supports Prostate Cancer Risk Assessment Across Diverse Cohorts

Artera’s (Los Altos, CA, USA) multimodal artificial intelligence (MMAI) platform is being featured in five abstracts at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting.... Read more

$Image: Vaginal and urine samples showing endometrial cancer (true positive case; upper row) and no malignant cells (true negative case; lower row). (Jones ER, Narine N, O\'Flynn H, et al. The Lancet Obstetrics, Gynaecology, & Women\'s Health (2026). DOI:10.1016/S3050-5038(26)00222-0.)$

See LabMedica in...

LabMedica

Mammoth Biosciences Presents AACC 2021 Disruptive Technology Award Finalist CRISPR-Based Detection Platform

Latest AACC 2021 News

Channels